Single-dose Ag85B-ESAT6-loaded poly(lactic-
Animals
Cytokines
/ metabolism
Dose-Response Relationship, Immunologic
Drug Liberation
Endocytosis
Epitopes
Female
Humans
Immunity
Immunity, Humoral
Immunization
Immunoglobulin G
/ metabolism
Macrophages
/ metabolism
Mice, Inbred C57BL
Mycobacterium tuberculosis
/ immunology
Nanoparticles
/ administration & dosage
Polylactic Acid-Polyglycolic Acid Copolymer
/ chemistry
Recombinant Fusion Proteins
/ metabolism
Spleen
/ cytology
Survival Analysis
THP-1 Cells
Th1 Cells
/ immunology
Tuberculosis
/ immunology
Tuberculosis Vaccines
/ immunology
Vaccination
Ag85B
ESAT6
Mycobacterium tuberculosis
PLGA
nanoparticles
vaccine
Journal
International journal of nanomedicine
ISSN: 1178-2013
Titre abrégé: Int J Nanomedicine
Pays: New Zealand
ID NLM: 101263847
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
24
5
2019
pubmed:
24
5
2019
medline:
13
7
2019
Statut:
epublish
Résumé
Bacillus Calmette-Guérin, the attenuated strain of In this study, we formulated PLGA nanoparticles (NPs) encapsulating the bivalent H1 antigen, a fusion of Under physiological conditions, NPs degraded slowly and the encapsulated H1 antigen was released over a period of weeks. As a proof-of-concept vaccine candidate, H1 NPs were efficiently internalized by the THP-1 human macrophages. Six weeks after a single-dose vaccination, H1 NP-immunized C57BL/6J mice showed significant increase in the production of total serum IgG ( Altogether, our findings highlight the significance of the H1-PLGA nanoformulation in terms of providing long-term protection in mice with a single dose.
Sections du résumé
BACKGROUND
BACKGROUND
Bacillus Calmette-Guérin, the attenuated strain of
METHODS
METHODS
In this study, we formulated PLGA nanoparticles (NPs) encapsulating the bivalent H1 antigen, a fusion of
RESULTS
RESULTS
Under physiological conditions, NPs degraded slowly and the encapsulated H1 antigen was released over a period of weeks. As a proof-of-concept vaccine candidate, H1 NPs were efficiently internalized by the THP-1 human macrophages. Six weeks after a single-dose vaccination, H1 NP-immunized C57BL/6J mice showed significant increase in the production of total serum IgG (
CONCLUSION
CONCLUSIONS
Altogether, our findings highlight the significance of the H1-PLGA nanoformulation in terms of providing long-term protection in mice with a single dose.
Identifiants
pubmed: 31118627
doi: 10.2147/IJN.S172391
pii: ijn-14-3129
pmc: PMC6501725
doi:
Substances chimiques
Ag85B-ESAT-6 fusion antigen
0
Cytokines
0
Epitopes
0
Immunoglobulin G
0
Recombinant Fusion Proteins
0
Tuberculosis Vaccines
0
Polylactic Acid-Polyglycolic Acid Copolymer
1SIA8062RS
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3129-3143Déclaration de conflit d'intérêts
Disclosure The authors report no conflicts of interest in this work.
Références
Expert Rev Vaccines. 2004 Feb;3(1):23-34
pubmed: 14761241
Respirology. 2018 Apr;23(4):359-368
pubmed: 29341430
Vaccine. 2010 Apr 30;28(20):3571-81
pubmed: 20226890
Pharm Res. 2008 Aug;25(8):1815-21
pubmed: 18373181
Vaccine. 2009 Nov 16;27(49):6894-904
pubmed: 19755145
J Drug Target. 2008 May;16(4):282-93
pubmed: 18446607
Hum Vaccin Immunother. 2016 Mar 3;12(3):806-28
pubmed: 26513024
PLoS Pathog. 2012;8(5):e1002607
pubmed: 22589713
Expert Rev Vaccines. 2010 Sep;9(9):1095-107
pubmed: 20822351
Lancet. 2013 Mar 23;381(9871):1021-8
pubmed: 23391465
Infect Immun. 1991 Apr;59(4):1558-63
pubmed: 1900811
Hum Vaccin Immunother. 2016 Apr 2;12(4):1056-69
pubmed: 26752261
PLoS One. 2013 Apr 29;8(4):e61885
pubmed: 23637922
Exp Parasitol. 2016 Nov;170:236-246
pubmed: 27663469
J Pharm Pharmacol. 2006 Jun;58(6):739-47
pubmed: 16734975
Int J Nanomedicine. 2014 May 06;9 Suppl 1:51-63
pubmed: 24872703
J Immunol. 1996 Oct 15;157(8):3527-33
pubmed: 8871652
J Immunol. 2006 Nov 1;177(9):6353-60
pubmed: 17056566
Pharm Res. 2010 Feb;27(2):350-60
pubmed: 20024670
AAPS J. 2013 Jan;15(1):85-94
pubmed: 23054976
FEMS Immunol Med Microbiol. 1998 May;21(1):19-28
pubmed: 9657317
Immune Netw. 2015 Apr;15(2):51-7
pubmed: 25922593
PLoS Pathog. 2012;8(6):e1002676
pubmed: 22719245
Polymers (Basel). 2011 Sep 1;3(3):1377-1397
pubmed: 22577513
Acta Biochim Biophys Sin (Shanghai). 2007 Apr;39(4):290-6
pubmed: 17417685
Front Cell Infect Microbiol. 2013 Mar 25;3:13
pubmed: 23532930
Infect Immun. 2001 May;69(5):2773-8
pubmed: 11292688
Curr Opin Immunol. 2003 Aug;15(4):450-5
pubmed: 12900278
Biomaterials. 2007 Dec;28(35):5344-57
pubmed: 17825905
Int J Nanomedicine. 2014 Feb 07;9:813-22
pubmed: 24550673
Vaccine. 1995 May;13(7):683-9
pubmed: 7668038
Infect Immun. 1995 Mar;63(3):804-10
pubmed: 7868250
Nature. 2011 Feb 24;470(7335):543-7
pubmed: 21350488
J Pharm Sci. 2013 Oct;102(10):3567-78
pubmed: 23873630
Clin Vaccine Immunol. 2009 Aug;16(8):1121-6
pubmed: 19515867
Vaccine. 2011 Mar 3;29(11):2100-9
pubmed: 21256189
Croat Med J. 2015 Apr;56(2):85-93
pubmed: 25891867
Eur J Pharm Biopharm. 2011 May;78(1):107-16
pubmed: 21182941
Clin Infect Dis. 2000 Jun;30 Suppl 3:S279-82
pubmed: 10875800
Vaccine. 2001 Feb 28;19(15-16):1940-50
pubmed: 11228364
Lancet. 1995 Nov 18;346(8986):1339-45
pubmed: 7475776
Rev Infect Dis. 1989 Mar-Apr;11 Suppl 2:S353-9
pubmed: 2652252
PLoS One. 2016 Feb 19;11(2):e0149167
pubmed: 26894562
Int Immunopharmacol. 2011 Oct;11(10):1557-63
pubmed: 21621649
Front Immunol. 2014 Apr 23;5:188
pubmed: 24795730
Int J Mol Sci. 2011;12(7):4282-93
pubmed: 21845078
PLoS One. 2011;6(11):e26684
pubmed: 22073184
AAPS PharmSciTech. 2013 Jun;14(2):585-92
pubmed: 23463262
J Control Release. 2005 May 5;104(1):67-77
pubmed: 15866335
Adv Drug Deliv Rev. 2016 Jul 1;102:73-82
pubmed: 26596558
Adv Drug Deliv Rev. 1997 Oct 13;28(1):5-24
pubmed: 10837562
AAPS PharmSciTech. 2004 Sep 13;5(4):e53
pubmed: 15760050
Microbes Infect. 2006 Aug;8(9-10):2484-91
pubmed: 16879999
Hum Vaccin. 2008 Jan-Feb;4(1):13-22
pubmed: 18376145
Int J Pharm. 2005 Jul 25;298(2):315-22
pubmed: 15961266